Highest-materiality recent filing
Bioventus Q2 revenue $153.2M (+4%), GAAP EPS $0.47; initiates strategic alternatives review
Q2 revenue $153.2M (+4% YoY); GAAP EPS $0.47 vs $0.11; non-GAAP EPS $0.22 vs $0.21.
Bioventus Q1 revenue up 7% to $132.1M; GAAP EPS $0.04, raises FY26 EPS and CFO guidance
Revenue $132.1M (+7% YoY); GAAP EPS $0.04 vs -$0.04; Non-GAAP EPS $0.15 vs $0.08 (+88%).
Bioventus Q4 GAAP EPS $0.21, revenue $157.9M; guides FY2026 sales $600-610M
Q4 revenue $157.9M (+2.8% reported, +10.0% organic); GAAP EPS $0.21 (vs $0.00); non-GAAP EPS $0.24; Adj. EBITDA $36.7M (+30%).
Bioventus Q3 GAAP EPS $0.05 vs -$0.08 YoY; organic revenue +8% to $138.7M
GAAP net income $3.2M vs $5.2M loss; diluted EPS $0.05 improved from -$0.08 YoY.
Bioventus Q2 organic revenue up 6.2%; EPS $0.11 vs loss; reaffirms FY2025 guidance
Revenue $147.7M (-2.4% reported); organic revenue +6.2%, driven by double-digit growth in Surgical Solutions and Restorative Therapies.
Bioventus receives FDA 510(k) clearances for TalisMann and StimTrial PNS products
FDA granted 510(k) clearance for TalisMann PNS system with integrated pulse generator for deeper/larger nerves.
Bioventus Q1 revenue $123.9M, organic +5%; Non-GAAP EPS $0.08, up 33% YoY, guidance reaffirmed
Q1 revenue $123.9M, reported -4.3% but organic +5.0%; GAAP net loss $0.04/share vs $0.08 prior.
Bioventus Q4 revenue $153.6M (+13.5%); FY2025 guidance implies 6-8% organic growth
Q4 net loss from cont ops $0.3M vs ($7.7M) prior year; adj EBITDA $28.3M (+28.3%).
Closed sale of Advanced Rehabilitation business to Accelmed Partners on Dec 31, 2024.
Bioventus Q3 revenue up 15% to $139M; raises FY2024 guidance midpoint
Q3 revenue $139.0M (+15.0% YoY); net loss improved to $5.4M from $8.8M; Adjusted EBITDA $23.6M (+8.4%).
Bioventus divests Advanced Rehabilitation business to Accelmed for up to $45M
Total cash consideration of $45M: $25M at close plus up to $20M in earn-outs.
Bioventus Q2 revenue up 10.3% (organic +13.9%); raises FY2024 guidance
Revenue $151.2M (+10.3% YoY); Pain Treatments +17.2%, Surgical Solutions +18.6% US.
Bioventus settles securities class action for $15.25M; insurers to cover ~$6.5M
Settlement amount $15.25M plus interest, subject to court approval; all claims against Bioventus and defendants dismissed.
Bioventus Q1 revenue $129.5M (+8.7% YoY), guides FY24 higher
Net loss from continuing ops $6.0M vs $100.0M prior year; diluted loss per share $0.07 vs $1.28.
Bioventus Q4 revenue up 7.6% to $135.4M; guides FY2024 sales $520-535M
Q4 revenue $135.4M (+7.6% reported; +14.3% organic); Pain Treatments grew >20%.
Bioventus LLC entered into Amendment No. 5 to Credit and Guaranty Agreement on Jan 18, 2024 with lenders and Wells Fargo as agent.
Bioventus appoints Robert Claypoole as President and CEO effective Jan 10, 2024
Claypoole appointed President and CEO effective Jan 10, 2024, succeeding interim CEO Anthony Bihl.
Bioventus reports Q3 net sales $120.8M (-6.1% YoY), raises 2023 adjusted EBITDA guidance
Net loss from continuing ops improved to $8.8M from $101.0M in Q3 2022; loss per share $0.12 vs $1.18.
Net loss from continuing ops $4.7M ($0.06 EPS loss) vs $7.7M loss in Q2 2022, improved.
Bioventus completes sale of Wound Business for $35M cash + up to $45M earn-out; net ~$30M for debt
Closed divestiture of TheraSkin and TheraGenesis to LifeNet Health on May 22, 2023.
Bioventus sells wound business to LifeNet Health for up to $85M
Total cash consideration up to $85M: $35M at close, $5M deferred, $45M earn-out.
Bioventus Q1 net loss $100M on $78.6M impairment; Adj. EBITDA $17M beats expectations
Net sales $119.1M (+1.5% YoY); net loss from cont. ops. $100.0M vs $14.4M loss prior year.
Bioventus delays Q1 10-Q filing; prelim revenue ~$119M, Adj. EBITDA ~$17M
Filing delayed due to complexity in tax structure and noncontrolling equity interest calculation.
Bioventus CEO Kenneth Reali departs; Anthony Bihl named interim CEO
CEO Kenneth Reali transitioned from role on April 3, 2023; resigned as director and officer on April 4.
Bioventus Q4 net loss $44.9M; FY22 net loss $213.4M; removes $350M CartiHeal liabilities
Net sales Q4 $125.8M (-3.5% YoY); Pain Treatments down 25.4% on higher rebate claims.
Bioventus deconsolidates CartiHeal after settlement, records $88.5M loss on disposal
Transferred CartiHeal shares to trustee and paid $10M to former securityholders under settlement agreement.
Bioventus settles CartiHeal option for $10M, eliminates up to $350M in contingent payments
Bioventus LLC paid $10M non-refundable to CartiHeal securityholders and $150k to expense fund.
Bioventus amends Q3 results with $189M impairment; cuts FY2022 guidance
Net loss of $145.7M ($1.76 loss per share) vs $2.3M loss in prior year; includes $189.2M non-cash impairment.
Bioventus warns of $185M-$205M impairment, rebate dispute; evaluating going concern
Preliminary review indicates a non-cash impairment charge of $185M to $205M for Q3 2022.
Bioventus Q3 net sales up 25.9% to $137.1M, but cuts full-year 2022 guidance sharply
Q3 net sales $137.1M (+25.9% YoY); net income $3.2M vs net loss $2.3M prior year.
Bioventus files CartiHeal audited financials: 2021 net loss $10.2M, zero revenue
CartiHeal had $0 revenue in 2021; net loss $10.2M; accumulated deficit $67.7M.
Bioventus Q2 net sales up 27.8% to $140.3M; net loss improves to $8.0M; updates FY22 guidance
Net sales of $140.3M (+27.8% YoY); organic growth of 8.1%. Surgical Solutions vertical up 77.2%.
Bioventus closes CartiHeal acquisition for $315M upfront; $80M term loan funded
Acquired CartiHeal for ~$315M upfront plus up to $135M in sales milestone earn-outs.
Bioventus amends CartiHeal acquisition, defers $215M upfront, lowers sales milestone to $75M
Deferred $215M of $315M upfront; paid in five tranches 2023–2027 with 8% annual interest.
Bioventus Q1 net loss $14.8M vs prior-year income; reaffirms FY22 guidance
Net sales $117.3M (+43.4% YoY as reported, +8.6% organic); Pain Treatments +25.3%, Restorative Therapies +57.5%, Surgical Solutions +67.6%.
As previously reported, Robert E. Claypoole succeeded Mr. Bihl as President and Chief Executive Officer of the Company on January 10, 2024.
As previously reported, Robert E. Claypoole succeeded Mr. Bihl as President and Chief Executive Officer of the Company on January 10, 2024.
Robert E. Claypoole has been appointed as the Company’s President and Chief Executive Officer, and as a Class III director of the Company, effective January 10, 2024
succeeding Anthony P. Bihl III, the Company’s current Interim President and Chief Executive Officer, in such roles.
and as a Class III director of the Company
On April 4, 2023, Anthony P. Bihl III was appointed as Interim Chief Executive Officer of the Company and as a Class III director of the Company, effective April 5, 2023.
On April 4, 2023, Anthony P. Bihl III was appointed as Interim Chief Executive Officer of the Company and as a Class III director of the Company, effective April 5, 2023.
On April 3, 2023, the Board of Directors (the “Board”) of Bioventus Inc. (the “Company”) informed Kenneth Reali that it had determined that he would transition from his role as Chief Executive Officer of the Company and, on April 4, 2023, Mr. Reali resigned as a director and officer of the Company.
On April 3, 2023, the Board of Directors (the “Board”) of Bioventus Inc. (the “Company”) informed Kenneth Reali that it had determined that he would transition from his role as Chief Executive Officer of the Company and, on April 4, 2023, Mr. Reali resigned as a director and officer of the Company.
On January 8, 2023, the Board of Directors (the "Board") of Bioventus Inc. (the "Company") appointed John A. Bartholdson to the Board as a Class II director effective on January 8, 2023.
On August 29, 2022, Stavros G. Vizirgianakis resigned as a member of the Board of Directors (the “Board”) of Bioventus Inc. (the “Company”), effective as of that date.
On June 27, 2022, John E. Nosenzo, Chief Commercial Officer of Bioventus Inc. (the “Company”), and the Company agreed on a transition plan providing for Mr. Nosenzo’s retirement from the Company, effective October 1, 2022.
Max materiality 0.90 · Median 0.70 · Most common event earnings